<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To define the histologic, cytogenetic (CG) and clinical spectrum of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) carrying an 8q24 (c-myc) translocation, 87 patients with an 8q24 aberration were identified from 785 consecutive successfully analyzed cases </plain></SENT>
<SENT sid="1" pm="."><plain>Aberrations involving 8q24 were found at diagnosis (n = 66) or at relapse/progression (n = 21) </plain></SENT>
<SENT sid="2" pm="."><plain>Histologically, Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) (32%) and Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) (19%) with 8q24 changes at diagnosis, was the most common </plain></SENT>
<SENT sid="3" pm="."><plain>Nevertheless, 46% of cytogenetically characterized <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> cases do not show 8q24 aberrations </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, 8q24 aberration was also often found in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) and low-grade NHL cases at progression </plain></SENT>
<SENT sid="5" pm="."><plain>Cytogenetically, a de novo group is represented by classical t(8;14)(q24;q32) (n = 41), with isolated 8q24 changes, fewer secondary CG changes and represent mostly <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> cases </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, cases carrying variant 8q24 aberrations (n = 29) contain more CG events, carried primary 14q32 translocations, and included most FL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and diffuse large B cell (DLBC) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases </plain></SENT>
<SENT sid="7" pm="."><plain>Clinically, the overall median follow-up was 8.6 months (range 0-192), with a median survival of 4.2 months from CG analysis </plain></SENT>
<SENT sid="8" pm="."><plain>The presence of a 8q24 aberration give a statistically significant inferior prognosis than its absence in <z:hpo ids='HP_0000001'>all</z:hpo> histological groups, independent of clinical prognostic factors, when analyzed both at diagnosis and at relapse </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the finding of an 8q24 aberration is of marked negative prognostic significance, either at diagnosis or at disease progression, in a variety of NHL </plain></SENT>
</text></document>